Skip to content
DataLookout
Menu

MONEONCT03979131

Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 37 words Show 5 more changesShow less
    • Study completion pushed from Jun 15, 2026 to Jun 15, 2027
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study description expanded, about 8 words
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 37 to confirmed 40
    • Primary completion date changed from estimate of Jan 15, 2023 to Mar 15, 2023
    • Site details revised
    v6
  3. Notable Primary completion date: Jun 15, 2022 to Jan 15, 2023v5
  4. Notable Primary completion date: Jun 15, 2021 to Jun 15, 2022v4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 15, 2019 to Aug 22, 2019
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Pathological complete response (pCR) rate
Timeframe: 7 years

Secondary (4)

Overall survival (OS)
Disease-free survival (DFS)
Progression-free survival (PFS)
Surgical complete resection rate (R0)

Arms and interventions

Resectable GC and GEJC+avelumab+FLOT preoperative treatmentExperimental

Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year.

Combination products: Avelumab addition to perioperative chemotherapy in GC and GEJC

Sites

1 site in 1 country

  • Vall d'Hebron Institute of OncologyBarcelona, Spain